<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 22, 1995
-----------------
IMRE CORPORATION
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
----------------------------------------------
(State or other jurisdiction of incorporation)
0-12943 22-2389839
- ------------------------ ---------------------------------
(Commission File Number) (IRS Employer Identification No.)
401 Queen Anne Avenue North
Seattle, Washington 98109
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (206) 298-9400
-------------------------------------------------------------
(Former name or former address, if changed since last report)
Page 1 of 6 Pages
Exhibit Index on Page 4
<PAGE>
ITEM 5. OTHER EVENTS
On November 22, 1995, IMRE Corporation (the "Company" or "IMRE") issued a
press release announcing receipt of a complaint that was filed in the United
States District Court for the Northern District of California, claiming that the
Company's PROSORBA-Registered Trademark- column allegedly infringes a patent
issued February 25, 1992 to David S. Terman, M.D. which was subsequently
assigned in July 1993 to DTER-ENT, Inc., a California corporation.
IMRE first received a notice of a claim of infringement from DTER-ENT,
Inc. in July 1993. The Company has reviewed the complaint with legal counsel
and believes that there is no merit to the claim. The Company intends to
vigorously defend against the action.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
20.1 Press release dated November 22, 1995.
Page 2
<PAGE>
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
IMRE CORPORATION
November 27, 1995 By /s/ Alex P. de Soto
- ------------------------- -------------------------------
Date Alex P. de Soto
Vice President,
Chief Financial Officer, and
Chief Accounting Officer
Page 3
<PAGE>
INDEX TO EXHIBITS
Exhibit Number Exhibit Page
- -------------- ------- ----
20.1 Press release dated November 22, 1995
Page 4
<PAGE>
FOR IMMEDIATE RELEASE
Contact: Alex P. de Soto
Chief Financial Officer
IMRE Corporation
(206) 298-9400
IMRE CORPORATION ANNOUNCES ALLEGED PATENT INFRINGEMENT
MOVES TO NEXT LEVEL
SEATTLE, WASHINGTON -- November 22, 1995 -- IMRE Corporation (NASDAQ: IMRE)
announced today receipt of a complaint that was filed with the United States
District Court, Northern District of California, claiming that the Company's
PROSORBA-Registered Trademark- column allegedly infringes a patent issued
February 25, 1992, to David S. Terman, M.D. which was subsequently assigned in
July 1993 to DTER-ENT, Inc., a California corporation.
IMRE first received a notice of a claim of infringement from DTER-ENT, Inc. in
July 1993. The Company has disclosed this claim in its public filings for the
past two years. This matter has been reviewed by two independent outside patent
counsel and in both instances, the Company was advised that the claims of the
patent allegedly infringed by the Company are invalid or unenforceable, or not
infringed. The Company will vigorously contest the alleged claim.
IMRE Corporation is a biotechnology company that is a leader in the field of
immunoadsorption treatment. The Company's first product, the PROSORBA-
Registered Trademark- column, has FDA marketing approval for the treatment of
idiopathic thrombocytopenic purpura (ITP), an immune-mediated bleeding disorder.
IMRE recently announced positive results of a clinical trial using the PROSORBA-
Registered Trademark- column for rheumatoid arthritis therapy and is developing
a rheumatoid arthritis prognostic assay. IMRE is currently conducting a pilot
clinical study using the PROSORBA-Registered Trademark- column in kidney
transplantation and is seeking corporate partners to help fund its clinical
programs.
###
